A common intracellular allosteric binding site for antagonists of the CXCR2 receptor: Research paper

British Journal of Pharmacology

Volumn 159, Issue 7, 2010, Pages 1429-1439

  Salchow, K ^a,b   Bond, Me ^a,c   Evans, Sc ^a,d   Press, Nj ^a   Charlton, Sj ^a   Hunt, Pa ^a   Bradley, Me ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Allosteric; CXCR2 receptor; Homology modelling; Mechanism of action; SB265610; Sch527123; Site directed mutagenesis

Indexed keywords

1 (2 BROMOPHENYL) 3 (7 CYANO 3H BENZOTRIAZOL 4 YL)UREA; 2 HYDROXY N,N DIMETHYL 3 [2 [[1 (5 METHYLFURAN 2 YL)PROPYL]AMINO] 3,4 DIOXOCYCLOBUT 1 ENYLAMINO]BENZAMIDE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); INTERLEUKIN 8; PTERIDONE 1; SB 265610; SCH 527123; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHO CELL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

ALLOSTERIC SITE; ANIMALS; BENZAMIDES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOBUTANES; FLOW CYTOMETRY; HUMANS; MODELS, MOLECULAR; PHENYLUREA COMPOUNDS; POINT MUTATION; RADIOLIGAND ASSAY; RECEPTORS, INTERLEUKIN-8B; TRIAZOLES;

EID: 77949861512     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00623.x     Document Type: Article

References (19)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M (2008). Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 29 (6 280 286.
3. Andrews G, Jones C, Wreggett KA (2008). An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 73 (3 855 867.
4. Artursson P, Tavelin S (2003). Caco-2 and emerging alternatives for prediction of intestinal drug transport: a general overview. In: van de Waterbeemd H, Lennernäs H, Artursson P (eds.). Methods and Principles in Medicinal Chemistry. John Wiley & Sons: München, Germany, pp. 72 82.
5. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G et al. (2004). Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 101: 11791 11796.
6. Birdsall NJ, Lazareno S (2005). Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 5 (6 523 543.
7. Bonnert R, Gardiner S, Hunt F, Walters I (2001). Pteridine compounds for the treatment of Psoriasis. Patent application WO/2001/062758.
8. Bradley ME, Bond ME, Manini J, Brown Z, Charlton SJ (2009). SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br J Pharmacol 158: 328 338.
9. Carter PH, Tebben AJ (2009). Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists. Methods Enzymol 461: 249 279.
10. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS (2009). CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121 (1 55 68.
11. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J et al. (2007). Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 322: 477 485.
12. Hausdorff WP, Campbell PT, Ostrowski J, Yu SS, Caron MG, Lefkowitz RJ (1991). A small region of the beta-adrenergic receptor is selectively involved in its rapid regulation. Proc Natl Acad Sci USA 88 (8 2979 2983.
13. He R, Browning DD, Ye RD (2001). Differential roles of the NPXXY motif in formyl peptide receptor signalling. J Immunol 166 (6 4099 4105.
14. Jespersen T, Grunnet M, Angelo K, Klaerke DA, Olesen SP (2002). Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes. Biotechniques 32 (3 536 538.
15. Kalatskaya I, Schüssler S, Blaukat A, Müller-Esterl W, Jochum M, Proud D et al. (2004). Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B2 bradykinin receptor. J Biol Chem 279 (30 31268 31276.
16. Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S et al. (2007). Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem 50 (17 3984 4002.
17. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C et al. (2008). Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74 (5 1193 1202.
18. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW (2009). Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30 (5 249 259.
19. Rovati GE, Capra V, Neubig RR (2007). The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71 (4 959 964.